5 min read
Tanruprubart may become the first targeted Guillain-Barré…
Annexon Biosciences reported that a single IV dose of tanruprubart, a C1q-blocking antibody, cut ventilator days by 28, ICU days by 7, and time to independent walking by 31 days versus placebo in a late-stage trial in Bangladesh and the Philippines. EMA review is underway for possible 2027 approval.